Home > Boards > US OTC > Biotechs > Sunshine Biopharma Inc. (SBFM)

Source for what? The links I provided show

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Gulo Member Profile
 
Followed By 2
Posts 8
Boards Moderated 0
Alias Born 02/10/02
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 4:55:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2021 12:37:30 PM
Information Statement - All Other (definitive) (def 14c) Edgar (US Regulatory) - 10/6/2021 6:01:19 AM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 9/21/2021 6:02:36 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2021 12:02:42 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/29/2021 4:47:38 PM
Sunshine Biopharma reports Q1 results Seeking Alpha - 5/13/2021 8:50:07 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2021 3:24:52 PM
Sunshine gets new patent application notice of allowance for adva-27a in Europe until 2033 Seeking Alpha - 3/11/2021 9:19:08 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 12:37:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 12:34:31 PM
Sunshine Bio launches COVID-19 treatment mice study Seeking Alpha - 2/10/2021 8:48:46 AM
SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY InvestorsHub NewsWire - 2/10/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS InvestorsHub NewsWire - 2/4/2021 8:00:00 AM
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING InvestorsHub NewsWire - 2/2/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB InvestorsHub NewsWire - 1/27/2021 8:20:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Capitalizes on Blockchain through StreamPay App InvestorsHub NewsWire - 1/26/2021 7:00:00 AM
SUNSHINE BIOPHARMA'S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK InvestorsHub NewsWire - 12/22/2020 8:00:00 AM
SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS InvestorsHub NewsWire - 12/8/2020 8:00:00 AM
SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET InvestorsHub NewsWire - 12/3/2020 8:00:00 AM
SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT InvestorsHub NewsWire - 12/1/2020 8:00:00 AM
Gulo   Tuesday, 03/05/13 02:04:41 PM
Re: Doc_John post# 5029
Post # of 102367 
Source for what? The links I provided show the abandonment of the application for the "Novel Difluorinated..." patent. The US8236935 "Podophyllotoxin" patent that was awarded last Aug is different.

The "Novel Difluorinated..." patent application was the broad patent that presumably overlapped too much with prior art. Sunshine refers to it under the PCT application number PCT/FR2003/002330.
http://www.sunshinebiopharma.com/technology.html

Curiously, ProtoKinetix also claims their IP is covered under this patent, citing WO 2004/014928 A2 (19 February 2004) (which is the WIPO patent number issued under the PCT/FR2003/002330 application).
http://www.protokinetix.com/aagp/patents/

To see for yourself, go to http://portal.uspto.gov/external/portal/pair/
and search for PCT number "PCT/FR2003/002330". The result will be "The related U.S. Application 10522365 is a National Stage Entry of PCT/FR03/02330". Click on the underlined 10522365 link to display the status of that application.

If you do the same for PCT/FR2007/000697, you'll see the new 8,236,935 patent. If you click on the transaction history tab, you'll see the it wasn't all smooth sailing. The original application got a final rejection Dec 20, 2011. The amended application was allowed Mar 2012, and issued Aug, 2012.

Sunshine/Advanomics Adva-27 should be protected under the recent patent (it is a CF2 stabilized version of podophyllotoxin), but I am sure Advanomics cannot lay claim to the difluoride technique in general. Given that the recent patent was initially rejected, but then was allowed after amendment, I can't begin to guess how well it will stand up to challenge. Analyzing the claims for these patents for comparison to the Sirona patents would be interesting and prove to be a pleasant 60-hour passtime for anyone that might be interested.


To be clear, the application and patent info for the two patents in question are:

WO2004/014928 = PCT/FR2003/002330 = CA 2492940 = US 10522365 = EPO 2003758183 (withdrawn 11.01.2011) = CN 03817770.6 NOVEL DIFLUORINATED GEM COMPOUNDS, PREPARATION METHODS THEREOF AND APPLICATIONS OF SAME

WO2007/125194 = PCT/FR2007/000697 = US 8,236,935 B2 = CA 2650384 = EP20070731356 = 2024379 (A1) = EP2024379 (B1) FR2900154 (A1) US2009318675 (A1) US8236935 (B2) WO2007125194 (A1) ES2353436 (T3) CA2650384 (A1) AT482225 (T) l NEW GEM-DIFLUORIDE C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND APPLICATIONS

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences